




Article

Mesenchymal Stem Cell-Mediated Deep Tumor Delivery of Gold Nanorod for Photothermal Therapy

Wan Su Yun ^{1,2,†}, Man Kyu Shim ^{2,†}, Seungho Lim ², Sukyung Song ², Jinseong Kim ^{1,2}, Suah Yang ^{1,2}, Hee Sook Hwang ³, Mi Ra Kim ⁴ , Hong Yeol Yoon ² , Dong-Kwon Lim ¹, In-Cheol Sun ² and Kwangmeyung Kim ^{1,2,5,*} 

¹ KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Korea

² Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea

³ Department of Pharmaceutical Engineering, Dankook University, Cheonan 31116, Korea

⁴ Department of Otorhinolaryngology-Head and Neck Surgery, Haeundae Paik Hospital, Inje University College of Medicine, Busan 48108, Korea

⁵ College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea

* Correspondence: kimkm@ewha.ac.kr

† These authors contributed equally to this work.

Abstract: Gold nanoparticles (AuNPs) with various sizes and morphologies have been extensively investigated for effective photothermal therapy (PTT) against multiple cancer types. However, a highly dynamic and complex tumor microenvironment (TME) considerably reduces the efficacy of PTT by limiting deep tumor penetration of AuNPs. Herein, we propose a mesenchymal stem cell (MSC)-mediated deep tumor delivery of gold nanorod (AuNR) for a potent PTT. First, MSCs are treated with tetraacylated N-azidomannosamine (Ac₄ManNAz) to introduce modifiable azide (N₃) groups on the cell surface via metabolic glycoengineering. Then, AuNRs modified with bio-orthogonal click molecules of bicyclo[6.1.0]nonyne (AuNR@BCN) are chemically conjugated to the N₃ groups on the MSC surface by copper-free click chemistry reaction, resulting in AuNR@MSCs. In cultured MSCs, the appropriate condition to incorporate the AuNR into the MSCs is optimized; in addition, the photothermal efficiency of AuNR-MSCs under light irradiation are assessed, showing efficient heat generation in vitro. In colon tumor-bearing mice, intravenously injected AuNR@MSCs efficiently accumulate within the tumor tissues by allowing deep tissue penetration owing to the tumor homing effect by natural tumor tropism of AuNR@MSCs. Upon localized light irradiation, the AuNR@MSCs significantly inhibit colon tumor growth by the enhanced photothermal effect compared to conventional AuNRs. Collectively, this study shows a promising approach of MSCs-mediated deep tumor delivery of AuNR for effective PTT.

Keywords: mesenchymal stem cell; gold nanorod; drug delivery; deep tumor penetration; photothermal therapy



Citation: Yun, W.S.; Shim, M.K.; Lim, S.; Song, S.; Kim, J.; Yang, S.; Hwang, H.S.; Kim, M.R.; Yoon, H.Y.; Lim, D.-K.; et al. Mesenchymal Stem Cell-Mediated Deep Tumor Delivery of Gold Nanorod for Photothermal Therapy. *Nanomaterials* **2022**, *12*, 3410. <https://doi.org/10.3390/nano12193410>

Academic Editor: Wen-Huei Chang

Received: 18 September 2022

Accepted: 27 September 2022

Published: 28 September 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction


Light-mediated therapeutic approaches have emerged as an effective cancer treatment owing to unique advantages, such as minimal invasiveness, high selectivity, and spatiotemporal control [1–3]. Photothermal therapy (PTT), which can convert light to heat via photothermal agents, causes irreversible damage in cancer cells by inducing localized heat depending on the magnitude of the light exposure time and its fluence in a non-invasive manner [4]. Importantly, gold nanoparticles (AuNPs) that have various size and morphology of spheres, rods, shells, clusters, and cages have been extensively investigated for effective PTT in diverse cancer types [5–7]. Importantly, the AuNPs efficiently accumulate within the tumor tissues owing to the enhanced permeability and retention (EPR) effect based on their nano-sized structure; in addition, the tumor targeting efficiency can be

further enhanced by modification with active-targeting ligands because AuNPs have great amenability for surface functionalization [8–11]. However, tumor tissues have a highly dynamic and complex microenvironment (TME), which is characterized by (i) regional blood flow to the tumors and increased vessel permeability; (ii) high stiffness, interstitial fluid pressure (IFP), and solid stress; and (iii) physical barriers imposed by the extracellular matrix (ECM) and increased ECM cross-linking [12,13]. These factors considerably reduce the tumor targeting efficiency of passive and active targeting strategies by limiting the deep tumor penetration of nanoparticles [14]. Therefore, there is a desperate need for a promising strategy to deliver AuNR to the deep tumor tissues for improving PTT efficiency.

Mesenchymal stem cells (MSCs) that can be easily isolated from fat liver, muscles, bone marrow, and many other places has become an attractive delivery system as a biovesicles to transport nanoparticles to tumor tissues [15]. The MSCs, that often lack major histocompatibility complex-II (MHC class II), prevent T cell responses and thus evade the immune systems complications in human and animal models [16]. Notably, MSCs exhibit natural tumor tropism premised on the site-specific expression of growth factors, such as epidermal growth factor, platelet-derived growth factor, and stromal-derived factor-1 [17]. Accordingly, they have an intrinsic homing nature to tumors by the activation of tumor-associated chemokine receptors; in addition to their tumor-targeting ability, recent studies have shown that MSCs hold a homing effect against specific tumors, which can be optimized by employing the appropriate types of MSCs to target a specific type of tumor [18]. Based on these distinct advantages, MSCs have been widely studied to enhance the deep tumor penetration of nanoparticles, which is mainly achieved by intracellular loading methods [19]. This is because the MSCs should encapsulate the nanoparticles based on physical and non-specific loading approaches owing to a lack of specific receptors compared to cancer cells [20]. However, this approach can diminish the natural functionality of MSCs and alter their *in vivo* fate; most importantly, it also shows limited drug loading efficiency, resulting in poor therapeutic efficacy.

Herein, we propose an MSCs-mediated deep tumor delivery of gold nanorod (AuNR) for a potent PTT by the incorporation of AuNR into the MSCs through metabolic glycoengineering and copper-free click chemistry reaction. The metabolic glycoengineering can incorporate modifiable chemical groups into the surface glycans of the cells [21–23]. When the cells are treated with unnatural metabolites such as Ac₄ManNAz, Ac₄GalNAz, and Ac₄GlcNAz, they utilize them to build blocks via an intrinsic glycan mechanism; as a result, azide (N₃) groups in such metabolites are exogenously generated on the cell surface [24]. The successful introduction of N₃ groups on the cell surface using unnatural metabolites was evaluated in stem cells as well as in various cancer (colon, breast, glioma, and prostate cancers) cells and normal (human fibroblast, cardiomyocytes, and human umbilical vein endothelial) cells, which was extensively employed for the biomedical application of tumor-specific imaging and drug delivery [21,23,25]. In particular, nanoparticles containing bio-orthogonal click molecules of bicyclo[6.1.0]nonyne (BCN) or dibenzylcyclooctyne (DBCO) can be chemically conjugated with N₃ group in the unnatural glycans by copper-free click chemistry reaction [25]. The important benefits of this strategy are in allowing high-amount loading of nanoparticles without affecting the intrinsic functions and fates of MSCs. Previous study has demonstrated a successful *in vivo* tracking of MSCs via magnetic resonance (MR) imaging by labeling the cells with superparamagnetic iron oxide nanoparticles via metabolic glycoengineering [26]. In this study, AuNRs modified with bio-orthogonal click molecules of BCN (AuNR@BCN) are prepared, and modifiable N₃ groups are introduced in MSCs by treating unnatural metabolites (Ac₄ManNAz) for metabolic glycoengineering; eventually, AuNR@BCN is incorporated into the MSCs (AuNR@MSCs) via copper-free click chemistry reaction (Scheme 1a). The AuNRs that are incorporated into the MSCs via copper-free click chemistry reaction of BCN and N₃ on the cell surface efficiently internalized into the cytoplasm of the MSCs owing to a membrane turnover mechanism. The biocompatibility of these nanoparticle internalization mechanisms by metabolic glycoengineering and copper-free click chemistry reaction has been evaluated,

and it did not affect stem cell function [25]. When the AuNR@MSCs are intravenously injected into the colon tumor models, they efficiently penetrate deep inside the tumor tissues via a stem cell homing effect and induce local hyperthermia upon light irradiation (Scheme 1b). In cell culture systems, the appropriate condition to incorporate the AuNR into the MSCs is optimized. In addition, the photothermal efficiency of AuNR-MSCs are assessed under light irradiation, showing efficient heat generation owing to a high AuNR-loading efficiency compared to conventional intracellular loading methods. The superior antitumor efficacy of AuNR-MSCs by deep tumor penetration is assessed in colon tumor-bearing mice. Collectively, this study shows a promising approach of MSCs-mediated deep tumor delivery of AuNR for an effective PTT.



Scheme 1. Mesenchymal stem cells deliver gold nanorod to deep tumor tissues for photothermal therapy. (a) AuNRs modified with bio-orthogonal click molecules of BCN (AuNR@BCN) are prepared, and modifiable N₃ groups are introduced into MSCs by treating unnatural metabolites (Ac₄ManNAz) for metabolic glycoengineering; eventually, AuNR@BCN is incorporated into the MSCs (AuNR@MSCs) via copper-free click chemistry reaction. The AuNRs that are incorporated into the MSCs via copper-free click chemistry reaction of BCN and N₃ on the cell surface efficiently internalized into the cytoplasm of the MSCs owing to a membrane turnover mechanism. (b) When the AuNR@MSCs are intravenously injected into the colon tumor models, they efficiently penetrate deep inside the tumor tissues via a stem cell homing effect and induce local hyperthermia upon light irradiation.

1.1. Reagents

Gold(III) chloride trihydrate, silver nitrate, hydrochloric acid, tetraethyl orthosilicate (TEOS), (3-aminopropyl)trimethoxysilane (APTMS), bicyclo[6.1.0]non-4-yn-9-ylmethyl N-succinimidyl carbonate (BCN-NHS), L-ascorbic acid, and sodium borohydride were purchased from Sigma Aldrich (Oakville, ON, USA). Cetyltrimethylammonium bromide (CTAB) was purchased from Tokyo Chemical Industry (TCI, Tokyo, Japan). Cyanine5.5 NHS ester was purchased from Lumiprobe (Hunt Valley, MD, USA). Tem grid (Carbon Film 200 Mesh copper) was purchased from Electron Microscopy Sciences (Hatfield, PA, USA). Human adipose-derived mesenchymal stem cells (MSCs) and HT29 (human colon adenocarcinoma) were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). RPMI 1640 medium, fetal bovine serum (FBS), penicillin, and streptomycin were purchased from WELGENE Inc. (Daegu, Korea). Minimum Essential Medium α , fetal bovine serum (FBS), Dulbecco's phosphate-buffered saline (DPBS), EZ-Link phosphine-PEG3-biotin, and streptavidin-conjugated horseradish peroxidase (streptavidin-HRP) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Cell counting kit-8 (CCK-8) was purchased from Vitascientific (Beltsville, MD, USA). Tetraacetylated N-azidoacetyl mannosamine (Ac₄ManNAz) was purchased from Invitrogen (Rockford, IL, USA).

1.2. Preparation and Characterization of AuNR@BCN

To incorporate the AuNRs into the MSCs via copper-free click chemistry reaction, BCN groups were introduced in the AuNRs. First, CTAB (3.6445 g, 0.1 M), HAuCl₄ (19.6865 mg, 0.01 M), AgNO₃ (1.69 mg), and ascorbic acid (176 mg, 0.1 M) were stirred at 1100 rpm for 3 min, resulting in AuNR@CTAB. Then, AuNR@CTAB was mixed with 0.8 mM CTAB solution, followed by incubation with 0.1 M NaOH and 1 M TEOS (20% v/v in MeOH) for 15 min. The resulting AuNR@SiO₂ was further mixed with APTMS (0.04 mL) at 4 °C for 24 h to yield AuNR@NH₂. Finally, the AuNR@NH₂, BCN-NHS ester, and Cy5.5-NHS ester were dissolved in DMSO, and the solutions were stirred for 24 h at 4 °C, resulting in AuNR@BCN.

1.3. Preparation and Characterization of AuNR@MSCs

In order to generate azide (N₃) groups on the MSC surface via metabolic glycoengineering, 5 × 10⁵ cells were seeded in the cell culture dishes, followed by treatment with 20 μM Ac₄ManNAz for 48 h. Then, the cells were further incubated with 10 mM BCN-Cy5.5 at 37 °C for 2 h. For the fluorescence imaging, the cells were washed twice with DPBS, fixed with 4% paraformaldehyde for 20 min, and stained with 4',6-diamidino-2-phenylindole (DAPI) for 15 min. The N₃ generation in the MSCs was observed via a Leica TCS SP8 laser-scanning confocal microscope (Leica Microsystems GmbH; Wetzlar, Germany) equipped with diode (405 nm), Ar (458, 488, 514 nm), and He-Ne (633 nm) lasers. To directly visualize the N₃ generation, fluorescence dye Cy5.5-conjugated BCN (BCN-Cy5.5, 2 μM), which can be chemically conjugated with N₃ on the cell surface, was further incubated with Ac₄ManNAz-treated MSCs. The successful N₃ generation on the MSC surface was also evaluated via Western blot analysis. Briefly, the Ac₄ManNAz-treated MSCs were lysed using RIPA buffer (1% SDS, 100 mM Tris-HCl, pH 7.4) with protease inhibitor for 1 h at 4 °C. After protein quantification by bicinchoninic acid protein assay (BCA), each 5 mg/mL cell lysate was mixed with 5 mM phosphine-PEG₃-biotin and incubated at room temperature for 12 h. The proteins from each sample were mixed with 1× sodium dodecyl sulfate (SDS) gel-loading dye and boiled for 5 min. Then, 5 μg of proteins was separated by 12% SDS-polyacrylamide gel electrophoresis and subsequently transferred onto polyvinylidene fluoride (PVDF). The membranes were incubated with 1× TBST (10 mol/L Tris, 100 mol/L NaCl, and 0.1% Tween 20, pH 7.4) containing 5% bovine serum albumin (BSA). Finally, the membranes were further incubated with 1× TBST containing streptavidin-HRP for 2 h at room temperature, and the protein band was visualized by an enhanced chemiluminescence kit.

To incorporate the AuNR@BCN in the Ac₄ManNAz-treated MSCs via copper-free click chemistry reaction, 5 × 10⁵ Ac₄ManNAz-treated MSCs were incubated with AuNR@BCN

at a 200 µg/mL concentration for 6 h. Successful AuNR incorporation in the MSCs (AuNR@MSCs) was observed via a Leica TCS SP8 laser-scanning confocal microscope (Leica Microsystems GmbH; Wetzlar, Germany) equipped with diode (405 nm), Ar (458, 488, 514 nm), and He-Ne (633 nm) lasers. The photothermal efficiency of AuNR@MSCs was assessed after light irradiation with a power of 1.0 W/cm² (CW laser, Changchun New Industries Optoelectronics Tech. Co. Ltd., Changchun, China). The real-time temperature and thermal images were recorded using a digital thermometer (HH506A, OMEGA, Norwalk, CT 06854, USA) and IR camera (E6, FLIR Systems, Seoul, Korea), respectively.

1.4. Deep Tumor Penetration of AuNR@MSCs in Colon Tumor Models

The deep tumor penetration of AuNR@MSCs was assessed in colon tumor-bearing mice, which were prepared via subcutaneous inoculation of 1×10^7 HT29 cells into the left flank. When the tumor volumes were approximately 200 mm³, AuNR@MSCs or AuNR@BCN with an equivalent concentration of 5 mg/kg of AuNR were intravenously injected into the mice. To administrate AuNR@MSCs with 5 mg/kg AuNR concentration, the amount of AuNR@MSCs were quantified by comparing with Cy5.5 fluorescence intensities of 5 mg/kg of AuNR@BCN (modified with Cy5.5). The tumor accumulation was observed by noninvasive near-infrared fluorescence (NIRF) imaging via an IVIS Lumina Series III system (PerkinElmer; Waltham, MA, USA). On day 5 after treatment, the major organs and tumor tissues were collected from the mice for ex vivo NIRF imaging, and fluorescence intensities were quantified using Living Image software (PerkinElmer, Waltham, MA, USA). In addition, tumor tissues from mice were cut into 10-µm thick sections for histology. Slide-mounted tumor sections were washed with DPBS three times and stained with GFP fluorescent dye-conjugated CD31 antibody at 4 °C for 12 h. Then, the nuclei of the tumor tissues were stained with DAPI for 15 min at dark condition and analyzed using a Leica TCS SP8 confocal laser scanning microscope (Fasanenstrasse 71, 10719 Berlin, Germany).

1.5. Therapeutic Efficacy and Toxicity Evaluation in Colon Tumor Models

The therapeutic efficacy and toxicity of AuNR@MSCs were assessed in HT29 tumor-bearing mice. Briefly, the mice were randomly divided into four groups: (i) saline, (ii) light irradiation only (Laser only), (iii) AuNR@BCN with light irradiation (AuNR+L), and (iv) AuNR@MSCs with light irradiation (AuNR@MSC+L). When the tumor volumes were approximately 100 mm³, AuNR@MSCs or AuNR@BCN with an equivalent concentration of 5 mg/kg of AuNR were intravenously injected into the HT29 tumor-bearing mice. In addition, tumor tissues in the Laser only, AuNR+L, and AuNR@MSC+L groups were locally irradiated by light with a power of 1.0 W/cm² for 5 min; light irradiation was performed after 3 days of AuNR@MSCs or AuNR@BCN treatment. The therapeutic efficacy was assessed by measuring the tumor volumes, calculated as the largest diameter \times smallest diameter² \times 0.53. The tumor volumes and body weights were measured every day, and mice with a tumor size of 2000 mm³ or higher were counted as dead.

1.6. Statistics

Statistical analyses were performed using GraphPad Prism 9 software (San Diego, CA 92108, USA). The statistical significance between two groups was analyzed using Student's *t*-test. One-way analysis of variance (ANOVA) was performed for comparisons of more than two groups, and multiple comparisons were analyzed using the Tukey–Kramer *post-hoc* test. Survival data were plotted as Kaplan–Meier curves and analyzed using the log-rank test. In the figures, statistical significance is indicated with asterisks (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).

1.7. Data Availability

All relevant data are available with the article and its Supplementary Information Files, or are available from the corresponding authors upon reasonable request.

2. Results and Discussion

2.1. Preparation and Characterization of AuNR@BCN

To incorporate the AuNR into the human adipose tissue-derived mesenchymal stem cells (MSCs) via metabolic glycoengineering and copper-free click chemistry reaction, AuNRs were modified with BCN (AuNR@BCN; Figure S1). The cetyltrimethylammonium bromide-stabilized gold nanorods (AuNR@CTAB) were used as a platform AuNPs due to their great amenability to modify its size, shape, and surface [5]. First, AuNR@CTAB was coated with silica (AuNR@SiO₂) because the protecting and shielding of the AuNR surface with silica shells can increase their stability and biocompatibility, resulting in the enhanced effectiveness of PTT [27]. The transmission electron microscope (TEM) images of the AuNR@SiO₂ clearly showed the silica-coated areas on the AuNR surface with a thickness of ~20 nm after modification of AuNR@CTAB (Figure 1a). To incorporate the bio-orthogonal click molecules onto the surface of AuNR, the AuNR@SiO₂ was functionalized with 3-aminopropyltriethoxysilane (APTES) using the Stöber method, resulting in AuNR@NH₂ [28]; finally, AuNR@BCN was obtained by the chemical conjugation of AuNR@NH₂ with BCN-succinimidyl carbonate (BCN-NHS ester) via copper-free click chemistry reaction. As shown in Figure 1a, there were no significant morphological changes in the AuNR@NH₂ and AuNR@BCN compared to AuNR@SiO₂, as confirmed by TEM images. The average size of AuNR@CTAB (about 80–90 nm) was slightly increased after silica-coating, wherein the AuNR@SiO₂, AuNR@NH₂, and AuNR@BCN have a similar average size of approximately 130–140 nm (Figure 1b). The zeta potential of AuNR@CTAB with high positive charge was changed to neutral after surface silica-coating, but that was reversed as a positive charge after modification with BCN (Figure 1c). Compared with the AuNR@CTAB (800 nm), the longitudinal SPR peaks of AuNR@SiO₂, AuNR@NH₂, and AuNR@BCN moved to 820 nm owing to the altered local environment around the AuNRs after silica-shell coating (Figure 1d). Next, the biocompatibility of AuNR@BCN was evaluated in the MSCs, showing no significant cytotoxicity after 48 h of treatment, with concentrations from 0 to 200 µg/mL (Figure 1e). Finally, the photothermal efficiency of each AuNR was assessed under light irradiation with a power of 1.0 W/cm². As shown in the photothermal images, the local temperature in the tubes was significantly increased up to 56 °C by AuNR@CTAB; in addition, AuNR@SiO₂, AuNR@NH₂, and AuNR@BCN showed comparable photothermal efficiency with AuNR@CTAB in the same experimental condition (Figure 1f,g). These results indicate that surface modification to incorporate the bio-orthogonal click molecules onto the surface of AuNR did not influence their basal photothermal efficiency. Taken together, as a photothermal agent modified with bio-orthogonal click molecules for incorporation into the MSCs, AuNR@BCN was successfully prepared without affecting the intrinsic characteristics of AuNRs, such as morphology, photothermal efficiency, and biocompatibility.




Figure 1. Preparation and characterization of AuNR@BCN. (a) TEM images of AuNR@CTAB, AuNR@SiO₂, AuNR@NH₂, and AuNR@BCN. (b) The size distribution of AuNR@CTAB, AuNR@SiO₂, AuNR@NH₂, and AuNR@BCN. (c) The zeta potential of AuNR@CTAB, AuNR@SiO₂, AuNR@NH₂, and AuNR@BCN. (d) UV spectrum of AuNR@CTAB, AuNR@SiO₂, AuNR@NH₂, and AuNR@BCN. (e) The viability of MSCs after 48 h of AuNR@BCN treatment with concentrations from 0 to 200 µg/mL. (f,g) The photothermal efficiency of AuNR@CTAB, AuNR@SiO₂, AuNR@NH₂, and AuNR@BCN under light irradiation with a power of 1.0 W/cm².

2.2. Optimization for Generation of Azide Groups on the Stem Cell Surface

In order to generate azide (N₃) groups on the surface of MSCs without affecting their intrinsic functions and fates, appropriate treatment periods and times of unnatural metabolites (Ac₄ManNAz) were optimized *in vitro*. When the MSCs were incubated with different concentrations of Ac₄ManNAz (0–50 µM) for 48 h, the amount of N₃ generated on the cell surface was gradually increased in a dose-dependent manner up to 20 µM, but that was similar in the MSCs treated with 20 or 50 µM (Figure 2a). The N₃ generation on the MSC surface was further visualized via cellular fluorescence imaging, wherein the MSCs were further incubated with BCN modified with fluorescent dye, Cy5.5 (BCN-Cy5.5), for 2 h after treatment and with Ac₄ManNAz (0–50 µM) for 48 h (Figure 2b). As expected, a strong Cy5.5 fluorescence signals on the cell surface were clearly observed in the MSCs treated with 20 µM Ac₄ManNAz, and those were similar with 50 µM Ac₄ManNAz-treated MSCs. Next, the cytotoxicity was evaluated by the different concentrations of Ac₄ManNAz treatments in MSCs. The result showed that treatment of up to 20 µM Ac₄ManNAz did not induce significant cell death of MSCs, but the cell viability of MSCs was significantly decreased compared to naive cells after 48 h of 50 µM Ac₄ManNAz treatment (Figure 2c). This significant cytotoxicity can potentially cause a negative effect on the intrinsic functions and fates of MSCs. These results are consistent with a previous study that demonstrated the safety of Ac₄ManNAz in stem cells [29]. Over 20 µM Ac₄ManNAz treatment led to the

inhibition of the functional properties of stem cells, such as proliferation rate, viability, rate of endocytosis, and genes related to cell adhesion. However, those effects by Ac₄ManNAz treatment were not observed in MSCs when they were treated with 20 μM Ac₄ManNAz. Therefore, we further optimized the appropriate treatment time of Ac₄ManNAz via cellular fluorescence imaging of MSCs treated with 20 μM Ac₄ManNAz; as described above, BCN-Cy5.5 was subsequently incubated with MSCs after Ac₄ManNAz treatment to visualize the N₃ on the cell surface (Figure 2d). The result indicates that N₃ generation on the MSC surface was gradually increased in an incubation time-dependent manner, but the amount of N₃ groups generated on the cell surface were nearly similar in MSCs after 48 or 72 h of Ac₄ManNAz treatment. In addition, the amounts of BCN-Cy5.5 conjugated with N₃ on the cell surface were significantly larger than the natural uptake of BCN-Cy5.5 that was confirmed in the MSCs without Ac₄ManNAz treatment (Figure S2). From these results, we can expect that drug loading into the MSCs via metabolic glycoengineering and copper-free click chemistry could be considerably higher than conventional intracellular loading methods. Taken together, these results clearly demonstrate that treatment with 20 μM Ac₄ManNAz for 48 h is the optimal condition to generate high amounts of N₃ groups on the MSC surface without affecting their intrinsic functions and fates.




Figure 2. Optimization for the generation of azide groups on the stem cell surface. (a,b) N₃ generation in the MSCs after 48 h treatment of Ac₄ManNAz with concentrations from 0 to 50 μM, confirmed by (a) Western blot analysis and (b) fluorescence imaging, respectively. (c) The viability of MSCs after 48 h of Ac₄ManNAz treatment with concentrations from 0 to 50 μM. (d) N₃ generation in the MSCs after 20 μM treatment of Ac₄ManNAz with different incubation times, * $p < 0.05$.

2.3. Preparation of AuNR-Incorporated MSCs (AuNR@MSCs) in Stem Cell Cultured System

Next, we prepared AuNR-incorporated MSCs (AuNR@MSCs) by the incubation of 20 μM Ac₄ManNAz-treated MSCs with AuNR@BCN. To efficiently monitor the AuNR incorporation in the stem cells via fluorescence imaging, AuNR@BCN modified with NHS-Cy5.5 (Cy5.5-AuNR@BCN) was used, wherein the Cy5.5-AuNR@BCN has BCN and Cy5.5 groups with a ratio of 9:1. First, the different concentrations (0–200 μg/mL) of Cy5.5-AuNR@BCN were treated with the Ac₄ManNAz-treated MSCs (Man⁺). The fluorescence signals (red color) of the AuNRs were clearly observed on the cell surface, and they became gradually stronger in a dose-dependent manner; however, those fluorescence signals in the AuNR@MSCs were similar after 200 or 400 μg/mL of AuNR@BCN treatment (Figure 3a).

Notably, the amount of AuNRs incorporated into the cells was significantly higher in MSCs treated with $Ac_4ManNAz$ compared to naive MSCs (Man^-). These results clearly indicate that metabolic glycoengineering-based nanoparticle incorporation allows a higher loading capacity in the stem cells than conventional intracellular loading methods. The AuNR incorporation efficiency was also evaluated at the different incubation times after the treatment of MSCs with $200 \mu\text{g}/\text{mL}$ AuNR@BCN (Figure 3b). The cellular fluorescence imaging results showed that the amount of AuNRs incorporated into the MSCs was nearly similar after 6 h and 12 h of AuNR@BCN treatment. The successful incorporation of AuNRs into the MSCs was further confirmed via cryogenic electron microscopy, which clearly shows nano-sized rod morphology on the cell surface after 6 h of $200 \mu\text{g}/\text{mL}$ AuNR@BCN treatment (Figure 3c).




Figure 3. Preparation of AuNR-incorporated MSCs (AuNR@MSCs) in stem cell cultured system. (a) Fluorescence images of $Ac_4ManNAz$ -treated or naive MSCs after incubation with different concentrations of Cy5.5-AuNR@BCN. (b) Fluorescence images of $Ac_4ManNAz$ -treated or naive MSCs after incubation with $200 \mu\text{g}/\text{mL}$ of Cy5.5-AuNR@BCN for 0, 1, 3, 6, or 12 h. (c) Optical images of $Ac_4ManNAz$ -treated or naive MSCs after incubation with $200 \mu\text{g}/\text{mL}$ of Cy5.5-AuNR@BCN for 6 h. (d) Photothermal efficiency of Man^+ / AuNR@BCN and Man^- / AuNR@BCN under light irradiation with power of $1.0 \text{ W}/\text{cm}^2$.

Hence, the photothermal performance of AuNR@MSCs, which were prepared by the treatment of 200 $\mu\text{g}/\text{mL}$ AuNRs for 6 h with MSCs pre-treated with 20 μM Ac4ManNAz for 48 h, was evaluated under light irradiation (808 nm, 1.0 W/cm^2). The photothermal images clearly showed a potent heat generation efficiency of AuNR@MSCs ($\text{Man}^+/\text{AuNR@BCN}$), wherein the local temperature in tubes was significantly increased up to 52 $^\circ\text{C}$, along with the light irradiation time being longer (Figure 3d and Figure S3). Importantly, an increase in local temperature by AuNR@MSCs was significantly higher compared to MSCs incorporating AuNRs via conventional intracellular loading methods ($\text{Man}^-/\text{AuNR@BCN}$; 39 $^\circ\text{C}$) after 6 min of light irradiation with a power of 1.0 W/cm^2 . Taken together, the AuNR@MSCs prepared by the incorporation of AuNRs in the stem cells through metabolic glycoengineering and copper-free click chemistry reaction show considerable heat generation efficiency by allowing a high loading capacity of photothermal agents.

2.4. Deep Tumor Penetration of AuNR@MSCs in Colon Tumor Models

The deep tumor penetration of AuNR@MSCs was assessed in colon tumor models that were prepared by the subcutaneous inoculation of 1×10^7 HT29 cells. When the tumor volumes were approximately 200 mm^3 , AuNR@MSCs or AuNR@BCN with an equivalent concentration of 5 mg/kg of AuNR were intravenously injected into mice.

Importantly, the tumor accumulation of AuNR@MSCs was significantly higher than that of AuNR@BCN, as confirmed by *in vivo* NIRF imaging of colon tumor-bearing mice (Figure 4a). The AuNR@MSCs in the tumor tissues was sustainably retained after 5 days of injection, whereas AuNR@BCN passively accumulated within the tumor tissues in the relatively lower levels and was rapidly removed from the tumors from 1 day of injection. These results are attributed to the natural homing effect by tumor tropism of stem cells. Quantitatively, the amount of AuNR@MSCs in the tumor tissues was 1.5–1.71-fold higher than AuNR@BCN on day 5 of injection (Figure 4b). *Ex vivo* NIRF images further showed 1.47–1.66-fold higher tumor accumulation of AuNR@MSCs than that of AuNR@BCN after 5 days of injection (Figure 4c). Histological analyses were additionally performed to confirm the deep tumor penetration of AuNR@MSCs. Interestingly, a strong Cy5.5 fluorescence (red color) of AuNR@MSCs was observed deep inside the tumor tissues along the CD31-positive blood vessels (green color) on day 5 of treatment (Figure 4d). Notably, AuNR@MSCs showed considerable accumulation in the whole region of the tumors compared with AuNR@BCN, indicating the efficient tumor accumulation of AuNRs by the MSC-mediated delivery strategy. More importantly, the Cy5.5 fluorescence (red color) of AuNR@MSCs was clearly observed in the central core region of the tumor tissues. These results demonstrate an effective deep tumor delivery of AuNRs by MSCs. As a control, only a little AuNR@BCN was observed in the tumor tissues owing to the limited targeting efficiency of nanoparticles by TME. These observations clearly demonstrate that AuNR@MSCs efficiently accumulate deep inside the tumor tissues via the intrinsic homing nature to tumors of stem cells [18]. From these results, we can also expect that AuNR@MSCs would promote a potent PTT under light irradiation owing to their considerable accumulation in whole tumor areas.




Figure 4. Deep tumor penetration of AuNR@MSCs in colon tumor models. (a) NIRF images of HT29 tumor-bearing mice after AuNR@MSCs or AuNR@BCN treatment. (b) Fluorescence intensities in the tumor tissues of HT29 tumor-bearing mice after AuNR@MSCs or AuNR@BCN treatment. (c) Ex vivo fluorescence images of major organs after 5 days of AuNR@MSCs or AuNR@BCN treatment. (d) Tumor tissues stained with fluorescent dye-conjugated anti-CD31 antibody after 5 days of AuNR@MSCs or AuNR@BCN treatment. Statistical significance is indicated with asterisks (***) $p < 0.001$).

2.5. Therapeutic Efficacy of PTT by AuNR@MSCs in Colon Tumor Models

The therapeutic efficacy of PTT by AuNR@MSCs under light irradiation was assessed in HT-29 colon tumor models. First, photothermal efficiency to generate heat under light irradiation was evaluated in mice (Figure 5a). Briefly, the mice were randomly divided into four groups of (i) saline, (ii) light irradiation only (Laser only), (iii) AuNR@BCN with light irradiation (AuNR+L), and (iv) AuNR@MSCs with light irradiation (AuNR@MSC+L). When the tumor volumes were approximately 100 mm³, AuNR@MSCs or AuNR@BCN with equivalent concentration of 5 mg/kg of AuNR were intravenously injected into the mice. In addition, tumor tissues in the Laser only, AuNR+L, and AuNR@MSC+L groups were locally irradiated by light with a power of 1.0 W/cm² for 5 min; light irradiation was performed after 3 days of AuNR@MSCs or AuNR@BCN treatment. The photothermal images of the mice showed significant hyperthermia in the tumor tissues in the AuNR@MSC+L group (47.4 °C) compared to the saline (35.4 °C), Laser only (40.7 °C), and AuNR@BCN+L (43.4 °C) groups. The high photothermal efficiency in localized tumor tissues is attributable to the high loading capacity of AuNR@MSC and their deep tumor penetration, resulting in considerable accumulation. Next, the therapeutic efficacy was assessed by monitoring tumor growth after treatment with the same protocol as described above (Figure 5b). As expected, the mice in the AuNR@MSC+L group (396.06 ± 10.42 mm³) showed significantly delayed tumor growth compared to those treated with saline (1758.2 ± 380.12 mm³), Laser only (1190.91 ± 290.75 mm³), and AuNR@BCN+L (857.08 ± 309.81 mm³) on day 18 of

treatment. The limited therapeutic efficacy of AuNR@BCN+L is due to the low tumor accumulation by highly dynamic and complex ECM that hinder deep tumor penetration of nanoparticles. With the intrinsic biocompatible characteristics of AuNPs, the body weights of mice in the AuNR@MSC+L or AuNR@BCN+L groups showed no significant changes compared to those in the saline group (Figure 5c). As a result, the median survival of mice in the saline, Laser only, and AuNR@BCN+L groups was determined to be 20, 24, and 28 days, respectively; wherein the mice were dead owing to the tumor progression (Figure 5d). In contrast, mice treated with AuNR@MSC+L all survived over 30 days and had significantly inhibited tumor growth. Consequentially, AuNR@MSC can promote intense hyperthermia in the tumor tissues under light irradiation via the MSC-mediated deep tumor delivery of AuNPs, leading to a potent PTT.




Figure 5. Therapeutic efficacy of PTT by AuNR@MSCs in colon tumor models. (a) Photothermal images of HT29 tumor-bearing mice after treatment with saline, Laser only, AuNR+L, or AuNR@MSC+L. (b) Tumor growth of HT29 tumor-bearing mice after treatment with saline, Laser only, AuNR+L, or AuNR@MSC+L. (c) Body weight changes during treatment. (d) Survival of mice after treatment with saline, Laser only, AuNR+L, or AuNR@MSC+L. Statistical significance is indicated with asterisks (** $p < 0.001$).

3. Conclusions

In this study, we proposed MSC-mediated deep tumor delivery of AuNRs to trigger a potent PTT in colon tumors. First, AuNRs modified with bio-orthogonal click molecules (AuNR@BCN) were prepared, and their size distribution, morphology, photothermal efficiency, and biocompatibility were assessed in vitro. Then, AuNR@BCN was incorporated

into the MSC via metabolic glycoengineering and copper-free click chemistry reaction. From these experiments, an appropriate condition to incorporate AuNR in the stem cells was carefully optimized. Importantly, the resulting AuNR@MSC showed high loading capacity compared to the conventional intracellular loading method, resulting in enhanced photothermal efficiency under light irradiation. Notably, the AuNR@MSC efficiently accumulated deep inside the tumor tissues owing to the tumor homing effect by the natural tumor tropism of stem cells when they were intravenously injected into the colon tumor models. As a result, the AuNR@MSC significantly inhibited colon tumor growth under local light irradiation. Overall, these findings suggested that MSC-mediated deep tumor delivery of AuNPs provide a new route for effective PTT. As such, this study introduced a novel technology for efficient delivery of nanoparticles using stem cells, which is potentially applicable for the treatment of a broad spectrum of diseases that require high targeting and deep tissue penetration.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/nano12193410/s1>, Figure S1. Schematic illustration to show the protocol for the preparation of AuNR@MSCs. Figure S2. Fluorescence image of MSCs treated with BCN-Cy5.5 (without Ac₄ManNAz treatment) for 48 h. Figure S3. The photothermal efficiency of Man⁺/AuNR@BCN and Man⁻/AuNR@BCN under light irradiation with a power of 1.0 W/cm².

Author Contributions: Conceptualization, K.K.; methodology, K.K., W.S.Y. and M.K.S.; validation, W.S.Y. and M.K.S.; formal analysis, K.K., W.S.Y. and M.K.S.; investigation, W.S.Y., M.K.S., S.L., S.S., J.K., S.Y., H.S.H., M.R.K., H.Y.Y. and I.-C.S.; resources, K.K. and D.-K.L.; data curation, K.K. and M.K.S.; writing—original draft preparation, K.K. and M.K.S.; visualization, K.K., W.S.Y. and M.K.S.; supervision, K.K.; project administration, K.K.; funding acquisition, K.K. and M.K.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants from the National Research Foundation (NRF) of Korea, funded by the Ministry of Science (NRF-2022M3H4A1A03067401 and NRF-2021R1C1C2005460). This work was supported by a grant from the Research year of Inje University in 2018—0035.

Data Availability Statement: All relevant data are available with the article and its Supplementary Information Files, or are available from the corresponding authors upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Choi, J.; Shim, M.K.; Yang, S.; Hwang, H.S.; Cho, H.; Kim, J.; Yun, W.S.; Moon, Y.; Kim, J.; Yoon, H.Y.; et al. Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy. *ACS Nano* **2021**, *15*, 12086–12098. [[CrossRef](#)]
2. Um, W.; Park, J.; Ko, H.; Lim, S.; Yoon, H.Y.; Shim, M.K.; Lee, S.; Ko, Y.J.; Kim, M.J.; Park, J.H.; et al. Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy. *Biomaterials* **2019**, *224*, 119494. [[CrossRef](#)]
3. Cho, I.K.; Shim, M.K.; Um, W.; Kim, J.-H.; Kim, K. Light-Activated Monomethyl Auristatin E Prodrug Nanoparticles for Combinational Photo-Chemotherapy of Pancreatic Cancer. *Molecules* **2022**, *27*, 2529. [[CrossRef](#)] [[PubMed](#)]
4. Jung, H.S.; Verwilt, P.; Sharma, A.; Shin, J.; Sessler, J.L.; Kim, J.S. Organic molecule-based photothermal agents: An expanding photothermal therapy universe. *Chem. Soc. Rev.* **2018**, *47*, 2280–2297. [[CrossRef](#)] [[PubMed](#)]
5. Sperling, R.A.; Rivera Gil, P.; Zhang, F.; Zanella, M.; Parak, W.J. Biological applications of gold nanoparticles. *Chem. Soc. Rev.* **2008**, *37*, 1896–1908. [[CrossRef](#)] [[PubMed](#)]
6. Siddique, S.; Chow, J.C.L. Application of Nanomaterials in Biomedical Imaging and Cancer Therapy. *Nanomaterials* **2020**, *10*, 1700. [[CrossRef](#)]
7. Siddique, S.; Chow, J.C.L. Recent Advances in Functionalized Nanoparticles in Cancer Theranostics. *Nanomaterials* **2022**, *12*, 2826. [[CrossRef](#)]
8. Torchilin, V. Tumor delivery of macromolecular drugs based on the EPR effect. *Adv. Drug Deliv. Rev.* **2011**, *63*, 131–135. [[CrossRef](#)]
9. Shim, M.K.; Park, J.; Yoon, H.Y.; Lee, S.; Um, W.; Kim, J.-H.; Kang, S.-W.; Seo, J.-W.; Hyun, S.-W.; Park, J.H.; et al. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy. *J. Control. Release* **2019**, *294*, 376–389. [[CrossRef](#)]
10. Shim, M.K.; Na, J.; Cho, I.K.; Jang, E.H.; Park, J.; Lee, S.; Kim, J.-H. Targeting of claudin-4 by Clostridium perfringens enterotoxin-conjugated polysialic acid nanoparticles for pancreatic cancer therapy. *J. Control. Release* **2021**, *331*, 434–442. [[CrossRef](#)]

11. Moore, J.A.; Chow, J.C. Recent progress and applications of gold nanotechnology in medical biophysics using artificial intelligence and mathematical modeling. *Nano Express* **2021**, *2*, 022001. [[CrossRef](#)]
12. Yhee, J.Y.; Jeon, S.; Yoon, H.Y.; Shim, M.K.; Ko, H.; Min, J.; Na, J.H.; Chang, H.; Han, H.; Kim, J.-H.; et al. Effects of tumor microenvironments on targeted delivery of glycol chitosan nanoparticles. *J. Control. Release* **2017**, *267*, 223–231. [[CrossRef](#)] [[PubMed](#)]
13. Kyu Shim, M.; Yang, S.; Sun, I.-C.; Kim, K. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery. *Adv. Drug Deliv. Rev.* **2022**, *183*, 114177. [[CrossRef](#)] [[PubMed](#)]
14. Peng, J.; Yang, Q.; Shi, K.; Xiao, Y.; Wei, X.; Qian, Z. Intratumoral fate of functional nanoparticles in response to microenvironment factor: Implications on cancer diagnosis and therapy. *Adv. Drug Deliv. Rev.* **2019**, *143*, 37–67. [[CrossRef](#)]
15. Dalby, M.J.; García, A.J.; Salmeron-Sanchez, M. Receptor control in mesenchymal stem cell engineering. *Nat. Rev. Mater.* **2018**, *3*, 17091. [[CrossRef](#)]
16. Le Blanc, K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. *Cytotherapy* **2003**, *5*, 485–489. [[CrossRef](#)]
17. Lim, S.; Yoon, H.Y.; Park, S.-J.; Song, S.; Shim, M.K.; Yang, S.; Kang, S.-W.; Lim, D.-K.; Kim, B.-S.; Moon, S.-H.; et al. Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomography. *Biomaterials* **2021**, *266*, 120472. [[CrossRef](#)]
18. Reagan, M.R.; Kaplan, D.L. Concise Review: Mesenchymal Stem Cell Tumor-Homing: Detection Methods in Disease Model Systems. *Stem Cells* **2011**, *29*, 920–927. [[CrossRef](#)]
19. Zhang, X.; Yao, S.; Liu, C.; Jiang, Y. Tumor tropic delivery of doxorubicin-polymer conjugates using mesenchymal stem cells for glioma therapy. *Biomaterials* **2015**, *39*, 269–281. [[CrossRef](#)]
20. Lv, F.-J.; Tuan, R.S.; Cheung, K.M.C.; Leung, V.Y.L. Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells. *Stem Cells* **2014**, *32*, 1408–1419. [[CrossRef](#)]
21. Shim, M.K.; Yoon, H.Y.; Ryu, J.H.; Koo, H.; Lee, S.; Park, J.H.; Kim, J.-H.; Lee, S.; Pomper, M.G.; Kwon, I.C.; et al. Cathepsin B-Specific Metabolic Precursor for In Vivo Tumor-Specific Fluorescence Imaging. *Angew. Chem. Int. Ed.* **2016**, *55*, 14698–14703. [[CrossRef](#)]
22. Shim, M.K.; Yoon, H.Y.; Lee, S.; Jo, M.K.; Park, J.; Kim, J.-H.; Jeong, S.Y.; Kwon, I.C.; Kim, K. Caspase-3/-7-Specific Metabolic Precursor for Bioorthogonal Tracking of Tumor Apoptosis. *Sci. Rep.* **2017**, *7*, 16635. [[CrossRef](#)] [[PubMed](#)]
23. Lee, S.; Jung, S.; Koo, H.; Na, J.H.; Yoon, H.Y.; Shim, M.K.; Park, J.; Kim, J.-H.; Lee, S.; Pomper, M.G.; et al. Nano-sized metabolic precursors for heterogeneous tumor-targeting strategy using bioorthogonal click chemistry in vivo. *Biomaterials* **2017**, *148*, 1–15. [[CrossRef](#)]
24. Yoon, H.Y.; Shin, M.L.; Shim, M.K.; Lee, S.; Na, J.H.; Koo, H.; Lee, H.; Kim, J.-H.; Lee, K.Y.; Kim, K.; et al. Artificial Chemical Reporter Targeting Strategy Using Bioorthogonal Click Reaction for Improving Active-Targeting Efficiency of Tumor. *Mol. Pharm.* **2017**, *14*, 1558–1570. [[CrossRef](#)]
25. Lim, S.; Kim, W.; Song, S.; Shim, M.K.; Yoon, H.Y.; Kim, B.-S.; Kwon, I.C.; Kim, K. Intracellular Uptake Mechanism of Bioorthogonally Conjugated Nanoparticles on Metabolically Engineered Mesenchymal Stem Cells. *Bioconjugate Chem.* **2021**, *32*, 199–214. [[CrossRef](#)] [[PubMed](#)]
26. Lim, S.; Yoon, H.Y.; Jang, H.J.; Song, S.; Kim, W.; Park, J.; Lee, K.E.; Jeon, S.; Lee, S.; Lim, D.-K.; et al. Dual-Modal Imaging-Guided Precise Tracking of Bioorthogonally Labeled Mesenchymal Stem Cells in Mouse Brain Stroke. *ACS Nano* **2019**, *13*, 10991–11007. [[CrossRef](#)] [[PubMed](#)]
27. Mine, E.; Yamada, A.; Kobayashi, Y.; Konno, M.; Liz-Marzán, L.M. Direct coating of gold nanoparticles with silica by a seeded polymerization technique. *J. Colloid Interface Sci.* **2003**, *264*, 385–390. [[CrossRef](#)]
28. Wong, Y.J.; Zhu, L.; Teo, W.S.; Tan, Y.W.; Yang, Y.; Wang, C.; Chen, H. Revisiting the Stöber Method: Inhomogeneity in Silica Shells. *J. Am. Chem. Soc.* **2011**, *133*, 11422–11425. [[CrossRef](#)]
29. Han, S.-S.; Shim, H.-E.; Park, S.-J.; Kim, B.-C.; Lee, D.-E.; Chung, H.-M.; Moon, S.-H.; Kang, S.-W. Safety and Optimization of Metabolic Labeling of Endothelial Progenitor Cells for Tracking. *Sci. Rep.* **2018**, *8*, 13212. [[CrossRef](#)]